Member Info for TorquayFan

Rigga - so does 27 pence LOL

"Don't they say a watched kettle never brews" - no they don't. They say a watched kettle never boils !

But it's true that a watched BB can be like 'doing time', (as an analogy), but when news arrives, it's nice. GNA

Scousemark - "Yes Ray won't be long before Eyor and friends turn up to damp down all this optomisum."

Do Eyor and Co have a problem with their eyes ?

Ah 'Puritas' - I remember him well. Much missed I daresay. Wouldn't it be fun to look back 10 years and view a lively days posting with Tosh and Lozan around too ! One thing for sure - with Puritas, Inan and others in full cry about the positives at that time, Scancell looked a force to be reckoned with . . . . . .

They were right broadly, Scancell has proved to be a 'force', BUT the wait has been a little longer than I expected !

Llass 08.20 - I like this bit : "I'm not going to limit my expectation that £1 will be the maximum because other shares jumped over 2000% on their news". That's quite right too but it won't get us up to the fabled GBP 8 !

In all seriousness, the potential SP here is very much upwards, but any quantifying of it will be hard to defend, until it happens . . . . the word is POTENTIAL for a whacking rise and there's bucketfulls of it !

Come on Scancell.

Hi Guys. can't get in to that - please can you copy here and is Scancell mentioned ? ATB

Aptly named 'Muddledup' - you wouldn't be posting here at all if it weren't for the 'Academics', Prof. Lindy in particular!

Thanks Bermuda , I'd have been surprised if DE had been involved, or indeed if DE this time, had the time, so credit where it's due as you say. Well done CH (and JC).

Crumbs : " Remember the days we used to moan about pr and under the radar etc etc lol". Yes I do and I wouldn't accept that then we were wrong. However, whilst we have not got a Piers Morgan or Bruce Forsyth (thank God) presenting on screen on our behalf, I think we have to give CH some credit for many of the positives flying around the Scancell orbit atm - much of it has come through on his watch. That's NOT to forget the impressive team building that has been going on in the last year or two and the reinforced financials.

Onwards then !

Crumbs I posted this today and similar yesterday - it would be good to hear from him : "NXC - With all your other preoccupations, I'm not sure you'll be around, but, if you are by any chance looking at the BB, regarding this weekend's blitz of SCLP publicity and the nice share rise, I wonder what your thoughts are about what might be going on? Did you have anything to do with it this time ?"

I guess he's very busy . . .

That's right Scousemark. And nearly 400 posts today with only a few from C7 and none from Inan - that must be a record for sure !! C7 I see from comments that you did OK today in your tests - great !

Crumbs - we have a 'tiger by the tail' for sure.

I saw earlier comments about 'very early stage' but as 'Covidity' is derived from the Immunobody platform, that's not strictly true is it ? Maybe Scancell are indeed well placed in the race for 2nd Gen and the 'T cells have it' - (I'm getting Parliamentary so back to sleep now).

Bermuda - I confess to clicking the link to 'Nature' updates from one of your posts some months ago - it's often a good read.

Familiar ? - "Killer cells - Alongside antibodies, the immune system produces a battalion of T cells that can target viruses. Some of these, known as killer T cells (or CD8+ T cells), seek out and destroy cells that are infected with the virus. Others, called helper T cells (or CD4+ T cells) are important for various immune functions, including stimulating the production of antibodies and killer T cells. T cells do not prevent infection, because they kick into action only after a virus has infiltrated the body. But they are important for clearing an infection that has already started. In the case of COVID-19, killer T cells could mean the difference between a mild infection and a severe one that requires hospital treatment, says Annika Karlsson, an immunologist at the Karolinska Institute in Stockholm. “If they are able to kill the virus-infected cells before they spread from the upper respiratory tract, it will influence how sick you feel,” she says. They could also reduce transmission by restricting the amount of virus circulating in an infected person, meaning that the person sheds fewer virus particles into the community.

T cells could also be more resistant than antibodies to threats posed by emerging variants. Studies by Sette and his colleagues have shown that people who have been infected with SARS-CoV-2 typically generate T cells that target at least 15–20 different fragments of coronavirus proteins1. But which protein snippets are used as targets can vary widely from person to person, meaning that a population will generate a large variety of T cells that could snare a virus. “That makes it very hard for the virus to mutate to escape cell recognition,” says Sette, “unlike the situation for antibodies.”

So when laboratory tests showed that the 501Y.V2 variant identified in South Africa (also called B.1.351) is partially resistant to antibodies raised against previous coronavirus variants, researchers wondered whether T cells could be less vulnerable to its mutations."

Full script here (hopefully) - mentions of Karolinska https://www.nature.com/articles/d41586-021-00367-7?

Thanks Bermuda re. 21.09 - interesting indeed. As was this - Ray P 19.12 "Future Research - We have identified a common process that occurs in most cancer that can be recognised by the immune system. This would allow us to design a vaccine to stimulate an immune response which would recognise and kill early cancerous cells. This may have to be boosted yearly as for seasonal flu vaccines. It could be given to people at high risk of cancer or to adults over 60 which are the most common age group for this disease." https://www.nottingham.ac.uk/medicine/people/lindy.durrant

Indeed LLass and you are. HValD to you - maybe you are our only contributor of the Lass variety ? And GLA

Thanks WTP - the NY Post - wow !

And thanks to you too Violindog - your insights have been invaluable and your devotion to duty inspiring. I hope you come through the next months with a flourish and of course, a retirement bonus from Lindy ! ATB

WF someone posted it was a Royal (British ?) Legion badge . . . earlier.

The best day and the best BB for Scancell, in many a long year ! GLA

and well done Rich 62 - here it is . . . .

https://www.mirror.co.uk/news/uk-news/universal-covid-vaccine-tackling-variants-23494665

. . . . "The DNA-based product seems to stimulate a good antibody and T-cell response. Scancell chief medical officer Dr Gillies O’Bryan-Tear, told The Telegraph: “We don’t necessarily claim it will be a pan-coronavirus vaccine, but it has got the potential to be so simply because of where it is targeted.” A number of other biotechs are working on similar jabs, including myNEO in Belgium, and Osivax in France. The latter has just completed a phase II clinical trial of a universal flu vaccine that also targets the N protein.

MyNeo, meanwhile, has used modelling to suggest which parts of the virus might remain stable longest, allowing them to maximise vaccine longevity. Other researchers in the US suggest using a previously-developed Sars vaccine, or a vaccine with several different coronaviruses programmed in, could stimulate broader protection. These products could not only protect against all variants of the pandemic Sars-CoV-2 virus, but other coronaviruses, like Sars and Mers, and future coronaviruses. However, universal Covid vaccines face significant hurdles. Experts note that scientists have been working for decades without success on a universal flu vaccine, for example.

Professor Danny Altmann, an immunologist at Imperial College, said: “It’s not science fiction, but it’s not trivial.” Scancell has had some funding from Innovate UK, but needs a big pharmaceutical partner in order to progress its new vaccine through clinical trials, and new investment of several hundred million pounds.

"But with this in place, and positive results from phase I/II trials, its vaccine could be developed within a year, it said. "There is no reason why, if we get a partner, we shouldn't be able to do it as quickly as the others have done it," said Dr O'Bryan-Tear, noting that the first coronavirus vaccines emerged less than a year after the pandemic began. However, scientists also stressed that at the moment there may not be a need for new vaccines. As yet, no evidence has conclusively shown that the existing vaccines are ineffective against the new variants, although others are expected to emerge.

Dr O’Bryan-Tear said: “I think the pandemic will be around for two or three more years, because of supply, because of not being able to vaccinate developing countries. During that time, the virus will mutate, so there are plenty of opportunities for new entrants to try their hand.” "

I think that's it - well done Inan.

https://www.telegraph.co.uk/news/2021/02/13/exclusive-universal-vaccine-can-conquer-covid-variants-could/